Movano Inc

MOVE | $0.484 -2.63% 26K

(0.0% 1d) (24.8% 1m) (-55.5% 1y) (0.0% 2d) (2.1% 3d) (-1.7% 7d) (-65.87% volume)
Earnings Calendar:
Market Cap: $ 47,540,933

Sec Filling | Patents | 15 employees

movano is a health-focused technology company that believes glucose is an important health metric to continuously track, as glucose levels serve as a proxy for metabolic health and risk for chronic disease, such as diabetes. we also believe that whether you are a person with diabetes, prediabetes or someone looking to pursue a healthier lifestyle, monitoring and managing your glucose levels shouldn’t be painful, complicated or conspicuous.

add to watch list Paper trade email alert is off

Palisade Bio Inc

PALI | $4.735 -6.61% -7.07% 140K

Manufacturing

(0.0% 1d) (1108.3% 1m) (167.6% 1y) (0.0% 2d) (-28.6% 3d) (14.7% 7d) (-90.71% volume)
Earnings Calendar: 2022-11-11
Market Cap: $ 60,470,756
https://www.palisadebio.com
Sec Filling | Patents | n/a employees

(US) Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

education msa gastrointestinal

add to watch list Paper trade email alert is off

Icecure Medical Ltd

ICCM | $1.23 -4.03% 120K

Manufacturing

(0.0% 1d) (1.3% 1m) (-11.0% 1y) (0.0% 2d) (-6.2% 3d) (-11.0% 7d) (-91.45% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 56,116,824
https://icecure-medical.com
Sec Filling | Patents | n/a employees

Founded in 2006, Israel-based IceCure Medical develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals.

treatment cancer urea israel kidney lung cancer lungs

add to watch list Paper trade email alert is off

COMPAGNIE DE SAINT GOBAIN

CODYY | $15.06 -0.13% 99K

Manufacturing

(0.0% 1d) (-3.8% 1m) (32.2% 1y) (0.0% 2d) (0.0% 3d) (-1.6% 7d) (-34.36% volume)
Earnings Calendar:
Market Cap: $ 38,135,911,804
https://www.saint-gobain.com/fr
Sec Filling | Patents | n/a employees

(FR)

add to watch list Paper trade email alert is off

Technicolor

TCLRY | $0.001 1000.0% 140K

Manufacturing

(0.0% 1d) (0.0% 1m) (-91.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (482.33% volume)
Earnings Calendar:
Market Cap: $ 9,596,094
https://www.technicolor.com/fr
Sec Filling | Patents | n/a employees

(FR)

add to watch list Paper trade email alert is off

POET TECHNOLOGIES INC.

POET | $1.02 -0.97% -0.98% 42K

Manufacturing

(0.0% 1d) (-23.2% 1m) (-71.4% 1y) (0.0% 2d) (0.0% 3d) (-3.6% 7d) (NaN% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 49,204,131
https://www.poet-technologies.com/
Sec Filling | Patents | 25 employees

(CA) poet technologies is a company based out of 121 richmond st w, toronto, ontario, canada.

add to watch list Paper trade email alert is off

Imunon Inc

IMNN | $1.16 3.11% 3.02% 95K

Manufacturing

(0.0% 1d) (40.9% 1m) (-6.4% 1y) (0.0% 2d) (2.6% 3d) (-20.4% 7d) (-36.41% volume)
Earnings Calendar:
Market Cap: $ 10,903,755
https://www.celsion.com
Sec Filling | Patents | 27 employees

(US) Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

vaccine treatment ovarian cancer cancer hepatitis

add to watch list Paper trade email alert is off